SCA
BOLD

Secor Capital Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

Secor Capital Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-45,232
Closed -$1.73M – 628
2018
Q2 		$1.73M Sell
45,232
-15,564
-26% -$576K 0.15% 216
2018
Q1 		$1.83M Buy
60,796
+44,871
+282% +$1.52M 0.15% 223
2017
Q4 		$498K Buy
+15,925
New +$437K 0.02% 368

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Secor Capital Advisors's BOLD Position: Q3 2018 in Review

Secor Capital Advisors sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2018, closing a stake of 45,232 shares — an estimated $1.73M sold.

Secor Capital Advisors first reported a position in BOLD in Q4 2017 and held it in 3 quarters. The position peaked at $1.83M in Q1 2018. 114 funds tracked by Wall St. Rank hold BOLD as of Q3 2018.

  • Secor Capital Advisors reported no remaining Audentes Therapeutics, Inc position as of Q3 2018 after selling out during the quarter.
  • Secor Capital Advisors sold 45,232 Audentes Therapeutics, Inc shares in Q3 2018, an estimated $1.73M.
  • Secor Capital Advisors first reported a position in Audentes Therapeutics, Inc in Q4 2017 and held it in 3 quarters.
  • Secor Capital Advisors's Audentes Therapeutics, Inc position peaked at $1.83M in Q1 2018.
  • 114 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2018.

Based on Secor Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.